Johnson & Johnson (JNJ) Stock Forecast & Price Target

Compare

26,551 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

JNJ Analyst Ratings

Moderate Buy

7 Buy

8 Hold

0 Sell

Based on 15 analysts giving stock ratings to

Johnson

& Johnson

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

JNJ Stock 12 Month Forecast

Average Price Target

$171.79

▲(12.72%Upside)

Based on 15 Wall Street analysts offering 12 month price targets for Johnson & Johnson in the last 3 months. The average price target is $171.79 with a high forecast of $185.00 and a low forecast of $159.00. The average price target represents a 12.72% change from the last price of $152.41.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"140":"$140","163":"$163","186":"$186","151.5":"$151.5","174.5":"$174.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":185,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$185.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":171.79,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$171.79</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":159,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$159.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[140,151.5,163,174.5,186],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,155.4,157.6769230769231,159.95384615384617,162.23076923076923,164.5076923076923,166.7846153846154,169.06153846153848,171.33846153846153,173.6153846153846,175.8923076923077,178.16923076923078,180.44615384615383,182.72307692307692,{"y":185,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,155.4,156.66076923076923,157.92153846153846,159.1823076923077,160.44307692307692,161.70384615384614,162.96461538461537,164.22538461538463,165.48615384615385,166.74692307692308,168.0076923076923,169.26846153846154,170.52923076923076,{"y":171.79,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,155.4,155.6769230769231,155.95384615384617,156.23076923076923,156.5076923076923,156.7846153846154,157.06153846153848,157.33846153846153,157.6153846153846,157.8923076923077,158.16923076923078,158.44615384615383,158.72307692307692,{"y":159,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":142.04,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":141.82,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":155.69,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":161.84,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":158.07,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":156.25,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":152.26,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":142.25,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":149.66,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":163.62,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":151.95,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":153.15,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":155.4,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$185.00

Average Price Target$171.79

Lowest Price Target$159.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$171

Buy

12.20%

Upside

Reiterated

06/18/25

Johnson & Johnson scores strongly due to its solid financial performance, robust earnings call guidance, and reasonable valuation. However, technical indicators suggest a neutral momentum, and the rejection of a subsidiary's bankruptcy plan introduces financial uncertainty, slightly dampening the overall score.

Larry BiegelsenWells Fargo

Wells Fargo

$186→$170

Hold

11.54%

Upside

Reiterated

06/26/25

Johnson & Johnson confirms Laminar LAAX IDE trial paused, says Wells FargoJohnson & Johnson confirms Laminar LAAX IDE trial paused, says Wells Fargo

Asad HaiderGoldman Sachs

Goldman Sachs

$176

Buy

15.48%

Upside

Reiterated

06/11/25

Strategic Positioning and Growth Potential Drive Buy Rating for Johnson & Johnson

Tim AndersonBank of America Securities

Bank of America Securities

$161

Hold

5.64%

Upside

Reiterated

06/06/25

Bank of America Securities Sticks to Its Hold Rating for Johnson & Johnson (JNJ)

David RisingerLeerink Partners

Leerink Partners

―

Hold

―

Reiterated

06/05/25

Analysts Offer Insights on Healthcare Companies: Teva Pharmaceutical (NYSE: TEVA), Johnson & Johnson (NYSE: JNJ) and Design Therapeutics (NASDAQ: DSGN)

Shagun Singh ChadhaRBC Capital

RBC Capital

$181

Buy

18.76%

Upside

Reiterated

06/05/25

Johnson & Johnson (JNJ) Gets a Buy from RBC Capital

Terence FlynnMorgan Stanley

Morgan Stanley

$169

Hold

10.89%

Upside

Reiterated

06/04/25

Cautious Hold Rating for Johnson & Johnson Amid Promising Oncology Advances and Competitive Challenges

Nico ChenDBS

DBS

$160

Hold

4.98%

Upside

Reiterated

05/30/25

Johnson & Johnson: Hold Rating Amid Stelara Patent Expiry and Strategic Acquisition

Joanne WuenschCiti

Citi

$185

Buy

21.38%

Upside

Assigned

05/22/25

Johnson & Johnson (JNJ) Gets a Buy from Citi

Matt MiksicBarclays

Barclays

$165

Hold

8.26%

Upside

Reiterated

04/29/25

Barclays Reaffirms Their Hold Rating on Johnson & Johnson (JNJ)

Josh JenningsTD Cowen

TD Cowen

$185

Buy

21.38%

Upside

Reiterated

04/28/25

Johnson & Johnson's Strategic Advancements in Electrophysiology: A Buy Rating by Josh Jennings

Morten HerholdtHSBC

HSBC

$180→$184

Buy

20.73%

Upside

Reiterated

04/28/25

Johnson & Johnson price target raised to $184 from $180 at HSBCJohnson & Johnson price target raised to $184 from $180 at HSBC

Danielle AntalffyUBS

UBS

$180

Buy

18.10%

Upside

Reiterated

04/16/25

UBS reiterates Buy Rating on Johnson Johnson (JNJ)UBS analyst Danielle Antalffy reiterated a Buy rating and $180.00 price target on Johnson Johnson (NYSE: JNJ).

Lee HambrightBernstein

Bernstein

$158→$159

Hold

4.32%

Upside

Reiterated

04/15/25

Hold Rating for Johnson & Johnson Amid Mixed Outlook and Macroeconomic Challenges

Jayson BedfordRaymond James

Raymond James

$165→$164

Buy

7.60%

Upside

Reiterated

04/14/25

Johnson & Johnson price target raised to $164 from $162 at Raymond JamesJohnson & Johnson price target raised to $164 from $162 at Raymond James

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$171

Buy

12.20%

Upside

Reiterated

06/18/25

Larry BiegelsenWells Fargo

Wells Fargo

$186→$170

Hold

11.54%

Upside

Reiterated

06/26/25

Johnson & Johnson confirms Laminar LAAX IDE trial paused, says Wells FargoJohnson & Johnson confirms Laminar LAAX IDE trial paused, says Wells Fargo

Asad HaiderGoldman Sachs

Goldman Sachs

$176

Buy

15.48%

Upside

Reiterated

06/11/25

Strategic Positioning and Growth Potential Drive Buy Rating for Johnson & Johnson

Tim AndersonBank of America Securities

Bank of America Securities

$161

Hold

5.64%

Upside

Reiterated

06/06/25

Bank of America Securities Sticks to Its Hold Rating for Johnson & Johnson (JNJ)

David RisingerLeerink Partners

Leerink Partners

―

Hold

―

Reiterated

06/05/25

Analysts Offer Insights on Healthcare Companies: Teva Pharmaceutical (NYSE: TEVA), Johnson & Johnson (NYSE: JNJ) and Design Therapeutics (NASDAQ: DSGN)

Shagun Singh ChadhaRBC Capital

RBC Capital

$181

Buy

18.76%

Upside

Reiterated

06/05/25

Johnson & Johnson (JNJ) Gets a Buy from RBC Capital

Terence FlynnMorgan Stanley

Morgan Stanley

$169

Hold

10.89%

Upside

Reiterated

06/04/25

Cautious Hold Rating for Johnson & Johnson Amid Promising Oncology Advances and Competitive Challenges

Nico ChenDBS

DBS

$160

Hold

4.98%

Upside

Reiterated

05/30/25

Johnson & Johnson: Hold Rating Amid Stelara Patent Expiry and Strategic Acquisition

Joanne WuenschCiti

Citi

$185

Buy

21.38%

Upside

Assigned

05/22/25

Johnson & Johnson (JNJ) Gets a Buy from Citi

Matt MiksicBarclays

Barclays

$165

Hold

8.26%

Upside

Reiterated

04/29/25

Barclays Reaffirms Their Hold Rating on Johnson & Johnson (JNJ)

Josh JenningsTD Cowen

TD Cowen

$185

Buy

21.38%

Upside

Reiterated

04/28/25

Johnson & Johnson's Strategic Advancements in Electrophysiology: A Buy Rating by Josh Jennings

Morten HerholdtHSBC

HSBC

$180→$184

Buy

20.73%

Upside

Reiterated

04/28/25

Johnson & Johnson price target raised to $184 from $180 at HSBCJohnson & Johnson price target raised to $184 from $180 at HSBC

Danielle AntalffyUBS

UBS

$180

Buy

18.10%

Upside

Reiterated

04/16/25

UBS reiterates Buy Rating on Johnson Johnson (JNJ)UBS analyst Danielle Antalffy reiterated a Buy rating and $180.00 price target on Johnson Johnson (NYSE: JNJ).

Lee HambrightBernstein

Bernstein

$158→$159

Hold

4.32%

Upside

Reiterated

04/15/25

Hold Rating for Johnson & Johnson Amid Mixed Outlook and Macroeconomic Challenges

Jayson BedfordRaymond James

Raymond James

$165→$164

Buy

7.60%

Upside

Reiterated

04/14/25

Johnson & Johnson price target raised to $164 from $162 at Raymond JamesJohnson & Johnson price target raised to $164 from $162 at Raymond James

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Johnson & Johnson

1 Month

xxx

Success Rate

14/24 ratings generated profit

Average Return

+0.98%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 58.33% of your transactions generating a profit, with an average return of +0.98% per trade.

3 Months

xxx

Success Rate

21/24 ratings generated profit

Average Return

+3.91%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 87.50% of your transactions generating a profit, with an average return of +3.91% per trade.

1 Year

Danielle AntalffyUBS

Success Rate

24/24 ratings generated profit

Average Return

+9.05%

reiterated a buy rating 3 months ago

Copying Danielle Antalffy's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +9.05% per trade.

2 Years

xxx

Success Rate

38/45 ratings generated profit

Average Return

+15.73%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 84.44% of your transactions generating a profit, with an average return of +15.73% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

JNJ Analyst Recommendation Trends

Rating

Feb 25

Mar 25

Apr 25

May 25

Jun 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, JNJ has received 21 Buy Ratings, 22 Hold Ratings, and 0 Sell Ratings. JNJ average Analyst price target in the past 3 months is 171.79.

Each month's total comprises the sum of three months' worth of ratings.

JNJ Financial Forecast

JNJ Earnings Forecast

Next quarter’s earnings estimate for JNJ is $2.68 with a range of $2.56 to $2.99. The previous quarter’s EPS was $2.77. JNJ beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.17% of the time in the same period. In the last calendar year JNJ has Outperformed its overall industry.

JNJ Sales Forecast

Next quarter’s sales forecast for JNJ is $22.84B with a range of $22.51B to $23.09B. The previous quarter’s sales results were $21.89B. JNJ beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.47% of the time in the same period. In the last calendar year JNJ has Outperformed its overall industry.

JNJ Stock Forecast FAQ

What is JNJ’s average 12-month price target, according to analysts?

Based on analyst ratings, Johnson & Johnson’s 12-month average price target is 171.79.

What is JNJ’s upside potential, based on the analysts’ average price target?

Johnson & Johnson has 12.72% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is JNJ a Buy, Sell or Hold?

Johnson & Johnson has a consensus rating of Moderate Buy which is based on 7 buy ratings, 8 hold ratings and 0 sell ratings.

What is Johnson & Johnson’s price target?

The average price target for Johnson & Johnson is 171.79. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $185.00 ,the lowest forecast is $159.00. The average price target represents 12.72% Increase from the current price of $152.41.

What do analysts say about Johnson & Johnson?

Johnson & Johnson’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 15 Wall Streets Analysts.

How can I buy shares of JNJ?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Johnson & Johnson (JNJ) Stock Forecast & Price Target

JNJ Analyst Ratings

JNJ Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Johnson & Johnson

JNJ Analyst Recommendation Trends

JNJ Financial Forecast

JNJ Earnings Forecast

JNJ Sales Forecast

JNJ Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts